ArticleScientific reports2025
DOT1L suppressed the proliferation of osteosarcoma cell line via modulating SYK/EGFR/P53 and SHP2-induced STING-NLRP3-pyroptosis signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Caspase-1 inhibition: mechanistic insights and comprehensive review of reported inhibitors to date.Inflammopharmacology · 2026Review
- The molecular mechanisms of pyroptosis and its implications in tumor immunotherapy.Molecular cancer · 2026Review
- Natural products reshape osteosarcoma cell fate: promoting cell death.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DOT1L, acting as a key epigenetic regulator, plays important roles in various biological processes, offering significant insights for the development of new cancer therapeutic strategies. This study investigates the impact of DOT1L on pyroptosis in osteosarcoma and its molecular mechanisms. Bioinformatics analysis was performed to identify genes associated with DOT1L. Western blotting was used to detect the expression levels of relevant proteins; flow cytometry was used to assess apoptosis in Saos-2 cells; transmission electron microscopy was used to observe the number of pyroptotic bodies in Saos-2 cells; subcutaneous xenograft experiments in nude mice were used to evaluate the progression of osteosarcoma; immunohistochemical staining was used to detect the expression of DOT1L, p-SYK, p-EGFR, p-SHP2, and NLRP3 in tumor tissues. Bioinformatics analysis revealed that DOT1L is associated with H3K79me2/3. Under hypoxic conditions and with cGAMP treatment, DOT1L promoted the expression of H3K79me2/3, SYK, EGFR, p-SYK, p-EGFR, p-STING, p-TBK1, p-IRF3, P53, NLRP3, IL-1β, GSDMD, and apoptosis in Saos-2 cells, while inhibiting the expression of p-SHP2 and SHP2. DOT1L mediated the SYK/EGFR/SHP2 signaling pathway to increase the number of pyroptotic bodies in Saos-2 cells. Additionally, DOT1L suppressed the progression of osteosarcoma and enhanced the expression of p-SYK, p-EGFR, and NLRP3 in tumor tissues, while inhibiting p-SHP2 expression. DOT1L suppressed the progression of osteosarcoma by modulating SYK/EGFR/P53 and SHP2-induced STING-NLRP3-pyroptosis signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.